Fiscal Year 2025 Department of Defense Prostate Cancer Research Program (PCRP)
Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Clinical Consortium Award **Go to:** • Program Announcement • General Application Instructions **Grants.gov Funding Opportunity Number:** HT942525PCRPCCA	Independent investigators with a faculty-level appointment (or equivalent)	• Supports a consortium that will facilitate the rapid execution of collaborative phase 2 or phase 2-linked phase 1 (phase 1/2) clinical trials that will bring to market high-impact, novel therapeutic interventions, which will significantly decrease the impact of prostate cancer. • One Coordinating Center and up to 11 Clinical Research Sites will be selected and will be jointly responsible for proposing, selecting, and conducting trials. • Funds ***may not*** be used for research or development of clinical protocols. • Applications should place significant emphasis on the incorporation of patients from high-risk and/or military populations (e.g., Service Members, Veterans). • Coordinating Center applications will identify two or more Affiliate Clinical Research Sites that must specialize in the recruitment of patients from high-risk populations to be supported and managed by the Coordinating Center. • Clinical Research Sites must provide plans for accruing patients from high-risk populations.	**Coordinating Center:** • The maximum allowable funding for the entire period of performance is **$10.5 million (M)** for total costs, including no less than **$500,000 per year** for support of two or more Affiliate Clinical Research Sites. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is **4** years. **Clinical Research Sites:** • The maximum allowable funding for the entire period of performance is **$2.0M** for total costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is **4** years.	**Pre-Application (Letter of Intent):** August 11, 2025 5:00 p.m. Eastern time **Application:** September 2, 2025 11:59 p.m. Eastern time

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Idea Development Award **Go to:** • Program Announcement • General Application Instructions **Grants.gov Funding Opportunity Number:** HT942525PCRPIDA	***Established Investigators:*** Independent investigators at all levels. ***New Investigators:*** Investigators who meet the following criteria at the application submission deadline date: • Have the freedom to pursue individual aims without formal mentorship • Have not previously received a non-mentored PCRP Award (excluding the Exploration Hypothesis-Development Award) • Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family medical leave)	• Supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY25 PCRP Overarching Challenges. • Emphasis is equally placed on Innovation and Impact. • Preliminary data are encouraged, but ***not*** required. • ***Clinical research is allowed.*** • ***Clinical trials are not allowed.*** • Each investigator may be named as the Principal Investigator on only one application. • Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. • **New Investigator Category:** The FY25 PCRP Idea Development Award mechanism encourages research ideas from investigators in the early stages of their careers. Applications submitted to the New Investigator category will be assessed using different review criteria for personnel and are required to include a collaborator(s) who has experience in prostate cancer research.	***Established Investigators:*** • The maximum allowable funding for the entire period of performance is **$1.7M** for total costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is **3** years. ***New Investigators:*** • The maximum allowable funding for the entire period of performance is **$2.1M** for total costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is **4** years.	**Pre-Application (Letter of Intent):** August 11, 2025 5:00 p.m. Eastern time **Application:** September 2, 2025 11:59 p.m. Eastern time